Recent research demonstrates that the propranolol oncolytic effect increases significantly when combined with Newcastle Disease Virus (NDV). Specifically, this combination targets canine mammary tumors (CMT), which often lack effective treatments for advanced stages. While NDV naturally kills tumor cells and triggers immunity, its effectiveness is usually limited by the host's antiviral responses. However, researchers have found that the non-selective beta-blocker propranolol can overcome these barriers.

The Role of IFN-I Signaling in the Propranolol Oncolytic Effect

The study utilized the CMT-U27 cell line to observe how propranolol interacts with the virus. Normally, NDV infection activates Type I interferon (IFN-I) signaling. This activation triggers the JAK-STAT pathway, which restricts viral replication within the tumor. Consequently, the therapeutic potential of the virus remains limited. By introducing propranolol, the researchers successfully suppressed NDV-induced IFN-I release. Furthermore, this intervention inhibited the activation of the JAK-STAT signaling pathway. Therefore, the propranolol oncolytic effect was enhanced through a significantly higher intratumoral viral load.

In Vitro and In Vivo Outcomes

During in vitro experiments, the combination therapy reduced tumor cell viability, migration, and invasion more effectively than NDV alone. Similarly, in xenograft models, both the virus and the combination therapy prolonged survival and suppressed tumor growth. Although both treatments showed efficacy, the combination markedly increased viral replication within the tumor. This finding suggests that propranolol creates a more permissive environment for oncolytic viruses. Additionally, this strategy offers a promising combined therapeutic approach for aggressive cancers that are otherwise resistant to virotherapy.

Clinical Implications for Comparative Oncology

While this study focused on canine models, the results carry weight for human oncology research. Many human cancers utilize similar JAK-STAT signaling to evade oncolytic treatments. Because propranolol is an affordable and well-characterized medication, repurposing it for oncology could provide a cost-effective synergy for modern virotherapy. Future trials must determine if these mechanisms translate directly to human clinical settings.

Frequently Asked Questions

How does propranolol help Newcastle Disease Virus kill cancer?

Propranolol inhibits the body's antiviral defenses, specifically the IFN-I and JAK-STAT pathways. By doing so, it allows the Newcastle Disease Virus to replicate more freely inside tumor cells, leading to more effective cell destruction.

Is this combination therapy safe?

In the CMT-U27 xenograft model, the combination therapy showed no significant increase in toxicity compared to NDV alone. However, further studies are required to establish safety profiles in human patients.

Why is the JAK-STAT pathway important in cancer therapy?

The JAK-STAT pathway often promotes tumor survival and limits the effectiveness of oncolytic viruses by triggering an antiviral state. Inhibiting this pathway can make tumors more susceptible to viral-mediated lysis.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or endorse specific treatments. Always consult with a qualified healthcare professional regarding any medical condition or treatment plan. Refer to the latest local and national guidelines for clinical practice.

References

1. Zhu Y et al. Propranolol enhances the oncolytic effect of newcastle disease virus on canine mammary tumor cell by modulating the IFN-I-mediated JAK-STAT signaling pathway. Vet Q. 2026 Dec 31. doi: 10.1080/01652176.2026.2648283. PMID: 41866332.


2. Hu et al. β-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer. NIH/PMC. 2021.


3. Hiller et al. Propranolol reduces inflammatory signaling and enhances immune cell recruitment in breast cancer. Phase 2 Triple-Blind Randomized Controlled Trial. 2020.